Higher R&D spend widens Celldex's Q2 loss, but a $324M offering extends the cash runway through 2028
CLDX has more than doubled off its 52-week low of $19.723.
Summary
Celldex's Q2 loss widened on higher R&D spending, but a $324M offering extended its cash runway through 2028. The company discontinued its Phase 2 PN study, while Phase 3 CSU topline data is expected in the coming months.
Updates
· Reuters — Q2 loss of $0.94 per share beat the $1.06 consensus estimate.
Key Events · Earnings and Guidance · CLDX
-
Q2 Loss Widens on Higher R&D
Net loss of $73.5M ($0.94/share) vs. $56.6M ($0.85/share) in Q2 2025, driven by a 25% increase in R&D expenses to $67.5M, primarily for barzolvolimab Phase 3 programs.
-
Cash Runway Extended Through 2028
Cash, equivalents, and marketable securities totaled $717.6M at June 30, 2026, up from $518.6M at year-end 2025, after net proceeds of $323.8M from an April 2026 public offering of 11.9M shares.
-
Phase 2 PN Study Discontinued
Barzolvolimab failed to meet primary or key secondary endpoints in a Phase 2 prurigo nodularis study; the program is being discontinued, removing a potential indication.
-
Phase 3 CSU Data Expected Soon
Topline data from two Phase 3 trials of barzolvolimab in chronic spontaneous urticaria are expected in September/October 2026; a BLA filing is planned for 2027 if positive.
Analysis · CLDX · Life Sciences
A 25% jump in R&D expenses to $67.5 million—fueled by the barzolvolimab Phase 3 programs in chronic spontaneous urticaria—pushed Celldex's Q2 net loss to $73.5 million, or $0.94 per share. The balance sheet, however, got a major lift from a $323.8 million public offering in April, leaving the company with $717.6 million in cash and investments at quarter-end and a runway that now stretches through 2028. On the pipeline front, the Phase 2 prurigo nodularis study was discontinued after barzolvolimab missed its endpoints, removing one potential indication. Attention now turns to the Phase 3 CSU topline data expected in September/October 2026—a near-term catalyst that could shape the company's commercial future.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLDX was trading at $41.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $19.72 to $41.74. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.